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Abstract
Background: Preference assessments of patients with rheumatoid arthritis can support clinical therapeutic
decisions for including biologic and targeted synthetic medicines to use. This study assesses patient preferences for
attributes of second-line therapies and heterogeneity within these preferences to estimate the relative importance
of treatment characteristics and to calculate the minimum benefit levels patients require to accept higher levels of
side effects.
Methods: Between November 2018 to August 2019, patients with rheumatoid arthritis were recruited to a survey
containing demographic and disease-related questions as well as a discrete choice experiment to measure their
preferences for second-line therapies using biologics or Janus kinases inhibitors. Treatment characteristics included were
route of administration, frequency of use, probability of mild short-term side effects, probability of side effects changing
appearance, probability of psychological side effects, probability of severe side effects and effectiveness of treatment.
Results: A total of 358 patients were included in the analysis. A latent class analysis revealed three preference patterns: (1)
treatment effectiveness as the single most important attribute, (2) route of administration as the most important attribute,
closely followed by frequency of use and psychological side effects and (3) severe side effects as the most important
attribute followed by psychological side effects. In addition, disease duration and mild side effects influenced the
patients’ choices.
Conclusion: Respondents found either effectiveness, route of administration or severe side effects as the most
important attribute. Patients noting effectiveness as most important were more willing than other patients to accept
higher risks of side effects.
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Key points
 Patients with rheumatoid arthritis found either
effectiveness of treatment, route of administration or
probability of severe side effects to be the most
important treatment attribute.
 Patients identifying effectiveness as most important
were more willing than other patients to accept
higher risks of side effects.
 This study could support shared decision-making by
recognising the different preference patterns of
patients.
 Results from this study have the potential to support
regulatory marketing authorisations of rheumatoid
arthritis treatments by revealing the minimum
acceptable benefit levels required to compensate
respondents for worsening levels of side effects.
Introduction
Information about patient preferences has long been con-
sidered important for supporting patient-centeredness in
clinical decisions [1]. Over the past decade, measuring pa-
tient preferences has evolved to use methods that quantify
preferences in the clinical context [2–5]; these approaches
have more recently also been used in rheumatology [6].
Recently, the interest in quantifying treatment preferences
of patients with rheumatic diseases has been expanded to
regulatory marketing authorisation decisions of new
rheumatic disease medicines [7, 8]. Quantitative assess-
ments of patient preferences may be important in regula-
tory marketing approvals in order to adjust decision-
making to patient opinions on the meaning and signifi-
cance of treatment attributes, such as the balance between
estimated effects and adverse reactions [9, 10]. A better
adjustment to patient preferences may also have a positive
impact on patient adherence [9].
Patients with rheumatoid arthritis (RA) are often
treated with multiple disease-modifying anti-rheumatic
drugs (DMARD). DMARDs have different modes of ac-
tion and characteristics, such as method and frequency
of administration and probability of adverse events or
monitoring requirements. Newly diagnosed patients with
RA usually start with conventional synthetic DMARDs
as first-line therapy. If first-line therapy is not tolerated
or is ineffective, biologics or Janus kinases (JAK) inhibi-
tors are recommended [11]. A potential advantage of
JAK inhibitors is that they are given orally rather than
subcutaneously or intravenously as is required for bio-
logics [12].
Previous research has shown that cost, efficacy, and
administration strongly influence patient preferences for
second-line therapy—i.e., biologics or JAK inhibitors
[2, 3, 13]. However, both biologics and JAK inhibitors
are associated with side effects such as infections,
increased blood and cholesterol levels, nausea, anxiety,
and skin rash [12]. Therefore, clinicians should provide
patients with specific information about treatments with
these medicines, including the extent and probability of
experiencing side effects. Although treatment costs can be
an important determinant of preference, they are less rele-
vant in countries with universal health care systems, as is
the case for most of Europe.
Clinicians need to understand their patients’ prefer-
ences and perspectives when informing them about po-
tential RA treatments so their patients can influence
decisions about their treatment to align with their pref-
erences [9, 10, 14]. Quantitative assessments of patient
preferences have the potential to support both clinicians
and regulators when they consider patient perspectives
[7, 12]. Currently there is a lack of evidence about the
extent to which patients feel that risks of side effects
would be acceptable for new second-line treatments.
This study assesses preferences regarding attributes of
second-line treatments and heterogeneity within these
preferences for patients with RA. These preferences are
used to estimate the relative importance of different
treatment characteristics and to calculate the minimum
benefit levels patient require in order to accept higher
levels of potential side effects.
Methods
Recruitment
Treatment preferences of patients with RA were assessed
using a discrete choice experiment (DCE). An invitation
to participate in the study was advertised to members of
the Swedish Rheumatism Association via email, news-
paper, newsletter, social media, mobile application, and
the association’s website. The invitation to participate
was also distributed to patients attending ten rheumatol-
ogy clinics in Sweden and via an online research panel
of patients with RA. A printed copy of the survey was
distributed by the Rheumatology clinic at Uppsala Uni-
versity hospital. All participants received information
about the study and provided their informed consent be-
fore completing the survey. The following inclusion cri-
teria were used: established RA diagnosis, 18–80 years of
age, and the ability to understand and answer the ques-
tions. Data were collected from November 2018 to
August 2019. The survey was approved by the regional
ethics review board in Uppsala, Sweden (Reg no. 2017/
521, 2018/156). Data generation, storage and sharing
were governed by the General Data Protection Regula-
tion (GDPR) Act, Uppsala University data protection
and security policies, and ethical consent provided.
Methodology of discrete choice experiment
DCE, a cross-sectional survey method used to assess prefer-
ences, allows for quantitative assessment of patient
Bywall et al. Arthritis Research & Therapy          (2020) 22:288 Page 2 of 10
preferences for health care policies, services, and interven-
tions [15]. DCE, which uses random utility theory (RUT),
aims to quantify the relative importance of one treatment
characteristic over another treatment characteristic. RUT
assumes that the value (utility) of a product can be deter-
mined by the value (utility) of the characteristics of that
product (i.e., attributes) and their levels. Respondents in a
DCE are presented with hypothetical scenarios (choice
questions) with varying attributes and levels. Respondents
are asked to choose their preferred option for each question
[16]. The utility can be estimated by modelling the choices
that respondents make between alternatives of treatments
that are described by different choice questions [17]. DCEs
can also be used to measure and explain heterogeneity
within the preferences of patients [18].
Attributes and levels
Using a step-wise approach, we identified attributes and
levels for inclusion in the DCE. First, the analysis of a lit-
erature review of previous studies of patient preferences
for DMARDs resulted in 12 potential treatment attri-
butes [2, 3, 5, 14, 19–24]. Second, the attributes and
levels identified in the literature review were discussed
with a rheumatologist to make sure that they reflected
current clinical practice. Third, three focus groups using
the nominal group technique (NGT) were conducted
with patients with RA (n = 7); these patients were asked
to identify new attributes and rank all potential attri-
butes from most to least important [25]. The focus
groups were audio recorded, lasted for about 90 min,
and conducted using an interview guide. Fourth, results
from the focus groups were discussed during several val-
idation meetings with one rheumatologist, the research
team, and two patient research partners. These meetings
revealed seven attributes: route of administration, fre-
quency of use, probability of mild short-term side ef-
fects, probability of side effects changing appearance,
probability of psychological side effects, probability of
severe side effects, and effectiveness of treatment.
Each attribute was revealed to have three levels based
on current clinical knowledge of existing biologics
and JAK inhibitors. Detailed information regarding
the selection and description of the attributes and
levels is available in the Supplementary material. All
attributes and levels included in the DCE are dis-
played in Table 1.
Experimental design and survey
The survey started with information about RA and avail-
able treatment options before entering the DCE. The last
section of the survey consisted of demographic and
disease-related questions, health literacy [26], and nu-
meracy [27]. The DCE had an attribute-based experi-
mental design. Respondents were asked to choose their
preferred treatment from two alternatives (see Fig. 1, ex-
ample of a choice question). The choice questions also
included a hover function with further explanations of
the attributes and the levels (see Supplementary file for
full text explanations of attributes and levels).
The survey was pilot tested with a subgroup (n = 22)
of patients with RA and patient research partners. Six of
the pilot tests were ‘think aloud’ interviews. The respon-
dents were encouraged to articulate their thoughts while
completing the survey. The language and the layout of
the survey were slightly changed after the pilot test.
Using the pilot test data, we fitted a multinomial logit
(MNL) model and used the beta estimates as priors for
the final experimental DCE design generated by NGene
1.0 (ChoiceMetrics, 2011), which is a d efficient (Bayesian)
design [28]. A constraint was posed on the design: route
of administration and frequency of use (e.g., if the route of
administration was a tablet, the frequency of use could
not be ‘monthly’). A total of 60 unique choice questions
were divided into four blocks. Each respondent had to an-
swer 15 unique choice questions. All attributes were dis-
played in each of the choice questions; three attributes
were identical across the two offered alternatives to reduce
the cognitive burden to respondents. We applied the
decision-making scenario ‘think of yourself in a situation
where your treatment is not working, your joints are swol-
len, you have pain or unbearable side effects and need to
change to a second-line treatment’.
Statistical analysis
SPSS® Statistics 20 and Nlogit® were used for analyses.
Demographic data were analysed using descriptive statis-
tics. Results were considered statistically significant if
P < 0.05. The patients’ preferences were determined by
attribute level estimates using a MNL model [29]. Latent
class analysis (LCA) models were used for further ana-
lysis of the DCE data. Such models account for the
multilevel structure of the data (i.e., every respondent
answered multiple choice questions) and account for the
investigation of preference heterogeneity. LCA models
assume that there are two or more latent classes of data
with different preferences. The classes are characterised
by unobserved latent variables that can be related to a
set of choice patterns. Once choice patterns have been
stratified into classes, it is possible for the model to de-
termine the probability that a respondent with certain
characteristics will be assigned to each class [30]. The at-
tributes were dummy coded (i.e., the mean effect for
each attribute was normalised at zero) except for effect-
iveness that was effects-coded. The ‘likelihood ratio test’
and the Akaike information criterion (AIC) were used to
determine the most appropriate model. A three-class
model based on the utility is displayed below:
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Fig. 1 Example of a choice question
Table 1 Attributes and levels
Attribute Level 1 Level 2 Level 3
Route of administration Tablet Injection Drip
Frequency of use Daily Weekly Monthly
Probability of mild short-term side
effects (nausea, vomiting or
headache)
Common 1 in 10 Uncommon 1 in 100 Rare 1 in 1000
Probability of side effects changing
appearance (hair loss, weight
changes or skin rash)
Common 1 in 10 Uncommon 1 in 100 Rare 1 in 1000
Probability of psychological side
effects (anxiety, mood changes,
depression or sleep disturbance)
Common 1 in 10 Uncommon 1 in 100 Rare 1 in 1000
Probability of severe side effects that
requires hospitalisation such as
severe infections or allergic reactions
Common 1 in 10 Uncommon 1 in 100 Rare 1 in 1000
Effectiveness (the ability to decrease
inflammation and swelling of the
joints, also pain and other
symptoms)
30% improvement. So out of
100 persons taking the
treatment, 30 will get enough
improvement; the rest will get
a small or no improvement
50% improvement. So out of
100 persons taking the
treatment, 50 will get enough
improvement; the rest will get
a small or no improvement
70% improvement. So out of
100 persons taking the
treatment, 70 will get enough
improvement; the rest will get
a small or no improvement
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Vrtajc ¼ β1jc Route of administrationTablet rtajc
þ β2jc Route of administrationIn jection rtajc
þ β3jc Frequency of useDaily rtajc
þ β4jc Frequency of useWeekly rtajc
þ β5jc Mild short − term side ef fects1 in 10 rtajc
þ β6jc Mild short − term side ef fects1 in 100 rtajc
þ β7jc Appearance side ef fects1 in 10 rtajc
þ β8jc Appearance side ef fects1 in 100 rtajc
þ β9jc Psychological side ef fects1 in 10 rtajc
þ β10jc Psychological side ef fects1 in 100 rtajc
þ β11jc Severe side ef fects1 in 10 rtajc
þ β12jc Severe side ef fects1 in 100 rtajc
þ β13jc Ef fectivenessrtajc
The utility component (V) describes the utility that re-
spondent ‘r’ belonging to class ‘c’ reported for alternative
‘a’ in choice question ‘t’. The attribute level estimates of
each attribute level are represented by β1–β13. A class
assignment model was fitted after the specified utility
function. Several demographic and disease-related vari-
ables were tested for their potential impact on class
membership in the LCA: age, gender, numeracy, health
literacy, education level, disease duration, occupational
status, and experience with DMARD treatment and side
effects. The final class assignment utility function was:
V rc ¼ β1jc disease durationr
þ β2jc and mild side effectsr
A significant attribute estimate within a certain class
indicates that this attribute contributes to the decision-
making process of respondents who belong to that class.
The sign of the beta indicates whether the attribute level
has a positive or negative effect on the utility.
To calculate the relative importance of the attributes,
the difference between the highest and lowest estimates
of the attribute level was calculated for each attribute.
The largest difference value was given a 1, representing
the attribute that was deemed most important by re-
spondents. The other difference values were divided by
the largest difference value, resulting in a relative dis-
tance between all other attributes and the most import-
ant attribute.
A minimum acceptable benefit (MAB) for changes in
attribute levels was calculated. The MAB is interpreted
as the minimum change in effectiveness that respon-
dents would require (on average) to accept changes to a
less desirable level in another attribute (probability of
getting a certain side effect by 10%, 1%, and 0.1%). MAB
was estimated as the difference between the preference
weights (parameters) for two levels ‘l’ of an attribute
divided by the preference weight, βk = effectiveness, which is








In total, 422 patients completed the full survey although
29 were removed after testing for flat-lining (choosing
option A at least 13 out of 15 times) and 35 were re-
moved because they answered the survey in under 5
min. Most of the respondents were female (77%). The
respondents represented all age categories between 18
and 80 years of age. The level of education was cate-
gorised into low (n = 105), medium (n = 86), or high (n =
162). A full overview of patient and disease characteris-
tics is presented in Table 2.
Preferences and relative importance
The multinomial logit model revealed that all of the at-
tribute estimates significantly contributed to the
decision-making process of respondents. The sign of the
beta indicates whether the attribute level has a positive
or negative effect on the utility. On average, respondents
preferred a tablet and injection over a drip (as indicated
by the positive estimates for tablet and injection). The
respondents also preferred monthly over weekly or daily
medication. A strong disutility for the highest frequency
of side effects was found in all classes. Finally, respon-
dents preferred the medicine with the highest effective-
ness. The directions of the effects of the attributes on
utility were as expected, which confirms that respon-
dents understood the choice questions. On average, the
most important attribute for respondents was the prob-
ability of severe side effects. Treatment effectiveness was
the second most important attribute, closely followed by
the probability of psychological side effects. Route of ad-
ministration came in fourth place followed by frequency
of use, probability of mild short-term side effects, and
side effects changing appearance.
Preference heterogeneity
Considerable heterogeneity was found in the prefer-
ences, as can be seen in the three classes representing
differences in preferences in Table 3. The average prob-
ability of respondents belonging to one of the classes
was 34%, 28%, and 38%, respectively. The model fit sig-
nificantly improved when including disease duration and
experience of mild short-term side effects (loglikelihod =
−2495 and − 2491, P < 0.05) to the class assignment
model.
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Although the directions of the impact of the attribute
levels on utility were the same in all classes, high levels
of heterogeneity were observed with respect to the im-
portance of the attribute levels. The relative importance
(RI) score of the attributes was separately calculated for
the three classes of the latent class analysis (Fig. 1). Ac-
cording to class 1, treatment effectiveness was the single
most important attribute. While in class 2, route of ad-
ministration was the most important attribute, closely
followed by frequency of use and psychological side ef-
fects. Severe side effects were the most important attri-
bute followed by psychological side effects for class 3.
Respondents with newly diagnosed RA and no experi-
ences of mild short-term side effects were more likely to
belong to class 2, whereas respondents with longer dis-
ease duration and previous mild short-term side effects
were more likely to belong to class 3 (Fig. 2).
Minimum acceptable benefit
Table 4 shows the minimum acceptable benefit (MAB)
levels required (in percentage point increases in effect-
iveness) to compensate respondents for worsening levels
of probability of certain side effects. Due to preference
heterogeneity, large differences were found in the MAB
across the three classes. In class 1, only a small benefit
was needed to accept a switch to a less favourable fre-
quency of side effects. In the other two classes, respon-
dents would require a larger increase in effectiveness to
accept an increase in risk of side effects. The highest
MAB levels were seen in class 3 respondents for moving
from a 0.1% probability of severe side effects to a 10%
probability, which required a 91.3 percentage point in-
crease in treatment effectiveness. The second highest
MAB level was seen in class 2 for moving from a 0.1%
probability of psychological side effects to a 10% prob-
ability, which required a 75.0 percentage point increase
in treatment effectiveness.
Table 2 Patient and disease characteristics













Low (elementary school, primary school,
real school or similar, 2-year high school
or vocational school, 3–4 year high school)
105 30
Medium (college or university shorter than 3 years) 89 25
High (college or university 3 years or longer) 162 45
Occupational status
Full time employee, part time employee, parental
leave/occupational leave
154 43
Work part time since RA, long-term sick leave,
sick pension
79 22











1–12 months 22 6
1–5 years 88 25
5–10 years 67 19
More than 10 years 179 50
Time till onset of drug effect
0–3 months 121 34
3–12 months 87 25
1–2 years 33 9
2–5 years 37 11
More than 5 years 32 9
Still not working 43 12
Table 2 Patient and disease characteristics (Continued)
Item N N in %
Experience with treatment
First line treatment only (csDMARDs) 182 51
Second line treatment, biologics 116 32
JAK inhibitors 12 3
Experience with side effects




No side effects 89 24
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Discussion
This study assesses preferences regarding second-line
treatment and heterogeneity within these preferences
among patients with RA as well as estimates of the rela-
tive importance of different treatment characteristics. In
addition, this study calculates the minimum benefit
levels patients require in order to accept higher levels of
potential side effects. Respondents found either effective-
ness of treatment, route of administration, or probability
of severe side effects to be most important. This study
also reveals that disease duration and experience with
mild side effects had an impact on patients’ choices. For
newly diagnosed patients with no experience of mild side
effects, route of administration (with oral administration
being most preferred) was the most important treatment
attribute. This preference might be due to wanting a
treatment that fits with current lifestyle, since taking a
tablet is less invasive and more convenient than a self-
administered injection or having an infusion [23]. In
addition, respondents might find it easier to understand
the impact of route of administration on daily life,
whereas relatively small changes in side effects may be
more complicated to understand.
Findings from this study are in line with previous re-
search reporting on different patterns of preferences of
patients with RA, as the importance of effectiveness and
severe side effects [2, 3, 13]. However, the attributes and
levels for this study address more side effects in the
Table 3 Preferences of patients based on latent class analysis
Class 1 estimate SE RI Class 2 estimate SE RI Class 3 estimate SE RI
Route of administration
Tablet 1.22*** 0.27 0.25 0.92*** 0.20 1.00 1.14*** 0.19 0.31
Injection 0.37** 0.17 0.51*** 0.15 0.64*** 0.16
Drip (ref)
Frequency of use
1 a day − 1.00*** 0.18 0.22 − 0.75*** 0.16 0.82 − 0.59*** 0.14 0.16
1 a week − 0.47*** 0.17 − 0.23 0.14 − 0.02 0.16
1 a month (ref)
Probability of mild short-term side effects
1 in 10 − 0.30* 0.17 0.06 − 0.27* 0.14 0.29 − 0.44** 0.17 0.12
1 in 100 − 0.15 0.13 − 0.08 0.12 − 0.06 0.14
1 in 1000 (ref)
Probability of side effects changing appearance
1 in 10 − 0.87*** 0.20 0.18 − 0.34** 0.16 0.11 − 1.55*** 0.21 0.42
1 in 100 − 0.04 0.17 − 0.10 0.14 − 0.48*** 0.15
1 in 1000 (ref)
Probability of psychological side effects
1 in 10 − 1.11*** 0.23 0.23 − 0.75*** 0.18 0.82 − 2.61*** 0.28 0.72
1 in 100 − 0.01 0.18 − 0.62*** 0.15 − 0.34** 0.17
1 in 1000 (ref)
Probability of severe side effects
1 in 10 − 1.75*** 0.27 0.36 − 0.21 0.18 0.23 − 3.65*** 0.39 1.00
1 in 100 − 0.82*** 0.16 − 0.08 0.12 − 0.79*** 0.16
1 in 1000 (ref)
Effectiveness (linear) 0.12*** 0.01 1.00 0.01** 0.00 0.43 0.04*** 0.00 0.44
Class probability model
Constant 1.32 0.96 2.51*** 0.96 – –
Disease duration − 0.16 0.12 − 0.32*** 0.12 – –
Experience with mild side effects − 0.46 0.36 − 0.99** 0.39 – –
Average class probability 0.34 0.28 0.38
“***,” “**” and “*” indicate significance at 1%, 5%, and 10%, respectively. RI relative importance
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choice questions, such as the probability of psychological
side effects or side effects changing appearance and the
probabilities of these side effects.
For patients whose choices were most influenced by
treatment effectiveness, the impact of side effects on
decision-making was marginal. These patients might be
recognised as a subgroup with increased willingness to
accept higher risk of side effects for an increase in effect-
iveness. Such patients might be willing to try a new or-
ally administered treatment even though there is
uncertainty regarding long-term safety outcomes. Newly
diagnosed patients preferred an oral medication over all
other attributes; however, they did not accept an
increased risk of severe side effects. Similarly, patients
with longer disease duration and experience with mild
side effects were less willing to accept a treatment with a
higher risk of severe side effects.
Previous studies have revealed that rheumatologists
and patients with RA have different treatment prefer-
ences [14, 31]. This study could support rheumatologists
and patients in shared decision-making by identifying
which attributes should be the focus of treatment discus-
sions. This study has also revealed the trade-offs that pa-
tients with RA are willing to make, a finding that may
help patients recognise what is most important from an
individual perspective. Tailoring treatment according to
Fig. 2 Relative importance score of attributes
Table 4 Minimum acceptable benefit for changes in attribute levels
Attribute Change Minimum acceptable benefit in percentage
Class 1 Class 2 Class 3
Probability of mild short-term side effects Moving from 0.1 to 10% 2.5 27.0 11.0
Moving from 0.1 to 1% 1.3 – 1.5
Moving from 1 to 10% 1.3 35.0 9.5
Probability of side effects changing appearance Moving from 0.1 to 10% 7.3 34.1 38.8
Moving from 0.1 to 1% – 10.0 12.0
Moving from 1 to 10% 7.6 24.0 26.8
Probability of psychological side effects Moving from 0.1 to 10% 9.3 75.0 65.3
Moving from 0.1 to 1% – 62.0 8.5
Moving from 1 to 10% 9.3 13.0 56.8
Probability of severe side effects Moving from 0.1 to 10% 14.6 21.0 91.3
Moving from 0.1 to 1% – 8.0 18.8
Moving from 1 to 10% 21.4 13.0 71.5
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patients’ preferences may increase treatment satisfaction
and compliance, which could improve treatment out-
comes in patients with RA [3].
For regulatory decision-making, considering prefer-
ence heterogeneity in marketing authorisations or in
post authorisations may lead to decisions that are more
acceptable to the end users. Treatment satisfaction may
increase for patients with a higher acceptance of side ef-
fects if the prospect of effectiveness is higher [32, 33].
There are some limitations of this study. First, several
sources were used to recruit patients with RA and there
was limited control over patient selection, it was not
possible to calculate the response rate. However, respon-
dents were only able to participate at one time and no
duplicates were found in the patient sample. The patient
characteristics (age, gender, education and treatment ex-
perience) suggest a representative sample of the Swedish
RA population [34]. This article provides a useful addition
to the literature by assessing the Swedish population. The
results may not be generalizable to other European coun-
tries as the health care systems are different. However,
there is some concordance between the results of similar,
previous studies in a range of countries [35].
Future research should focus on other important
disease-related characteristics such as disease activity
and risk propensity, characteristics that may influence
respondents’ preferences. Research needs to develop
methods and guidelines to bring in the results of patient
preference assessments in both regulatory marketing ap-
proval decisions and in the clinical context of shared
decision-making.
Conclusions
Respondents’ choices were most influenced by effective-
ness of treatment, route of administration or probability
of severe side effects. Patients who found effectiveness of
treatment to be most important only reported a mar-
ginal impact of side effects; these patients might be
recognised as a subgroup of patients more willing to
accept higher risk of side effects for increased effective-
ness. Other patients may not accept a switch associated
with increased risk of severe side effects. This study
could support personalisation of treatment with second-
line treatment by recognising the different preference
patterns of patients and the minimum acceptable levels
of benefit. Consideration of preference heterogeneity in
marketing authorisations or in post authorisations may
lead to decisions more acceptable to the end users.
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